Frank Tadashi Zenke

Chief Scientific Officer

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Cancer Biology Cancer Biology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Frank Tadashi Zenke is the Chief Scientific Officer at FoRx Therapeutics in Switzerland. His research primarily focuses on DNA damage response inhibitors in cancer therapy, with recent publications exploring the efficacy of ATR inhibitors, their role in various cancer types, and the impact of selective ATM inhibition. He is dedicated to understanding the mechanisms behind drug interactions and resistance in cancer treatments.

Articles (11)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

yvette drew

Associate Professor

The University of British Columbia

CANADA

View details

ronan broderick

Institute of Cancer Research

UNITED KINGDOM

View details

Dragomir Krastev

Institute of Cancer Research

UNITED KINGDOM

View details

Nicola Curtin

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Frank Tadashi Zenke

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

The Novel ATR Inhibitor Tuvusertib (M1774) Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs

Mapping combinatorial drug effects to DNA damage response kinase inhibitors

ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer

Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death

Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors

SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response

SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies

Collaborators (4)

yvette drew

ronan broderick

Dragomir Krastev

Nicola Curtin

Make your next move.